Drug Trial Radar · NCT05730283
Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin
Last checked: Nov 20, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
105
Planned (sponsor's estimate)
Start
Jun 2, 2025
Primary completion
Feb 29, 2028
Study completion Feb 29, 2028
Sponsor
- Lead sponsor
- Kevin WinthropAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute on Deafness and Other Communication Disorders (NIDCD); National Center for Advancing Translational Sciences (NCATS); Oricula Therapeutics; University of Washington; National Jewish Health; Mayo Clinic; The University of Texas Health Science Center at Tyler; Medical University of South Carolina; University of California, San Francisco; Johns Hopkins University; Northwell Health
- First posted
- Feb 15, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to test the effectiveness of the study drug, ORC-13361, in preventing hearing loss in patients with NTM infection who are undergoing treatment with IV amikacin therapy. The main question this study aims to answer is: * Is ORC-13661 effective for preventing or lessening hearing loss induced by amikacin treatment? * Is ORC-13661 effective for preventing or lessening other measures of hearing impairment? Participants will be asked to take a study drug while they are being treated with IV amikacin. Participants will take study drug for 90 days or until the end of their amikacin treatment, whichever comes first. During this time, researchers will gather clinical data on the participants' health. Researchers will compare three groups - two groups taking different doses of the study drug and one group taking a placebo drug - to see if dose of drug has any effect on preventing hearing loss. A placebo is a look-alike substance that contains no active drug.
Conditions
- Ototoxicity, Drug-Induced
Interventions
ORC-13661Drug
High-dose intervention (30mg daily)
ORC-13661Drug
Low-dose intervention (12mg daily)
PlaceboDrug
Placebo intervention
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mitigation or Prevention of OtotoxicityTime frame: Baseline to 28 (±5) days after study treatment discontinuation or 28 days after 90 days of study treatment, whichever comes first.
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
University of California, San Francisco
San Francisco, California · Recruiting
National Jewish Health
Denver, Colorado · Recruiting
Johns Hopkins University
Baltimore, Maryland · Recruiting
Mayo Clinic
Rochester, Minnesota · Withdrawn
Northwell Health
Manhasset, New York · Recruiting
Oregon Health & Science University
Portland, Oregon · Recruiting
Medical University of South Carolina
Charleston, South Carolina · Recruiting
University of Texas Health Science Center
Tyler, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.